0
Signin
countryflagCA

888-969-2592

RY 144.17 0.4529% TD 77.39 0.0517% SHOP 78.87 -1.3878% CNR 171.64 0.5625% ENB 50.09 -0.4769% CP 110.62 0.6277% BMO 128.85 -0.548% TRI 233.58 1.1563% CNQ 103.29 -0.174% BN 60.87 -0.2295% ATD 75.6 -1.447% CSU 3697.0 1.1582% BNS 65.76 -0.3485% CM 66.6 -0.5525% SU 54.21 1.1569% TRP 53.15 0.3398% NGT 58.54 -0.3405% WCN 226.5 0.4123% MFC 35.905 0.9986% BCE 46.75 -0.5954%

Oncolytics Biotech Inc

Healthcare CA ONC

1.56CAD
-0.01(0.64%)

Last update at 2024-05-16T19:30:00Z

Day Range

1.551.60
LowHigh

52 Week Range

1.484.49
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -24.75100M -26.25485M -22.50506M -33.12289M -16.48918M
Minority interest - - - - -
Net income -24.83500M -26.30428M -16.71835M -58.16123M -17.03722M
Selling general administrative 11.49M 4.28M 1.52M 0.91M 1.01M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.39M 0.45M 0.45M 0.49M 0.10M
Ebit -28.56900M -26.23494M -25.45901M -20.69336M -16.31569M
Ebitda -28.17700M -25.66436M -27.84557M -7.59898M -16.22031M
Depreciation and amortization 0.39M 0.57M -2.38657M 13.09M 0.10M
Non operating income net other - - - - -
Operating income -28.56900M -26.23494M -25.45901M -20.69336M -16.66268M
Other operating expenses 26.92M 26.23M 25.46M 20.69M 16.66M
Interest expense 0.53M 0.10M 0.00000M 0.32M 0.17M
Tax provision 0.08M 0.05M 0.00000M 0.00000M 0.55M
Interest income 0.53M 0.02M 0.12M 12.43M 0.17M
Net interest income 0.53M 0.10M 0.12M 0.18M 0.17M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.08M 0.05M -5.78670M 25.04M 0.55M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 26.92M 26.23M 25.46M 20.69M 16.66M
Cost of revenue - - - - 0.00000M
Total other income expense net 3.82M -0.01991M 2.95M -12.42953M 0.17M
Discontinued operations - - - - -
Net income from continuing ops -24.83500M -26.30428M -22.50506M -33.12289M -17.03722M
Net income applicable to common shares -24.83500M -26.30428M -22.50506M -33.12289M -17.03722M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 37.33M 45.88M 34.35M 19.66M 14.87M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.02M 2.78M - 1.50M 0.70M
Total liab 10.83M 9.78M 9.59M 19.77M 8.67M
Total stockholder equity 26.50M 36.10M 24.75M -0.10789M 6.20M
Deferred long term liab - - - - -
Other current liab 1.48M 2.40M 2.46M 12.53M 0.06M
Common stock 404.04M 391.35M 356.82M 311.08M 285.19M
Capital stock 404.04M 391.35M 356.82M 311.08M 285.19M
Retained earnings -418.25100M -393.41561M -367.11133M -344.60627M -311.48338M
Other liab 6.73M 6.73M 6.73M 6.73M 5.86M
Good will - - - - -
Other assets 1.00M - - - -
Cash 11.67M 41.26M 31.22M 14.15M 13.70M
Cash and equivalents 11.67M 1.36M 0.86M 1.09M 3.72M
Total current liabilities 3.94M 2.69M 2.71M 12.87M 2.81M
Current deferred revenue - - - - 0.93M
Net debt -11.29300M -40.60729M -30.81752M -13.64175M -13.69988M
Short term debt 0.22M 0.29M 0.25M 0.34M 0.00000M
Short long term debt - - - - -
Short long term debt total 0.37M 0.65M 0.40M 0.51M -
Other stockholder equity 40.05M 37.78M 34.64M 32.96M 31.88M
Property plant equipment 0.65M 0.98M 0.61M 0.73M 0.41M
Total current assets 35.68M 44.90M 33.74M 18.93M 14.45M
Long term investments - - - - -
Net tangible assets 26.50M 36.10M 24.75M -0.10789M 6.20M
Short term investments 20.47M 39.90M 30.36M 13.06M 9.98M
Net receivables 0.52M 0.87M 0.09M 2.07M 0.05M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.25M 1.99M 1.81M 3.17M 1.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.66M 0.39M 0.40M 0.46M 0.61M
Additional paid in capital - - - - -
Common stock total equity - - 356.82M 311.08M 285.19M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.00M - - 0.73M 0.41M
Deferred long term asset charges - - - - -
Non current assets total 1.65M 0.98M 0.61M 0.73M 0.41M
Capital lease obligations 0.37M 0.65M 0.40M 0.51M -
Long term debt total 0.16M 0.36M 0.15M 0.17M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -20.40300M -0.28595M -0.02931M -0.01090M -0.10747M
Change to liabilities 1.66M 0.18M -1.36820M 1.35M -1.31046M
Total cashflows from investing activities -20.40300M -0.28595M -0.02931M -0.01090M -0.10747M
Net borrowings -0.38100M -0.36551M -0.46072M -0.44750M -0.44750M
Total cash from financing activities 12.21M 33.02M 39.77M 21.02M 13.30M
Change to operating activities -1.61600M -0.31445M -0.40113M -1.12602M 0.46M
Net income -24.83500M -26.30428M -22.50506M -33.12289M -17.03722M
Change in cash -29.59600M 10.04M 17.07M 0.45M 1.86M
Begin period cash flow 41.26M 31.22M 14.15M 13.70M 11.84M
End period cash flow 11.67M 41.26M 31.22M 14.15M 13.70M
Total cash from operating activities -23.35500M -22.43401M -22.06844M -19.90612M -11.92024M
Issuance of capital stock 12.57M 32.91M 38.30M 18.00M 13.17M
Depreciation 0.39M 0.45M 0.45M 0.49M 0.10M
Other cashflows from investing activities -20.34800M - - 0.00000M 0.00000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.34M -0.77639M 1.98M -2.01712M 4.77M
Sale purchase of stock 0.01M 0.47M 1.94M 13.33M 12.85M
Other cashflows from financing activities 0.01M 0.47M 1.94M 3.47M 0.12M
Change to netincome 0.70M 4.33M -0.21935M 14.53M 1.12M
Capital expenditures 0.06M 0.29M 0.03M 0.01M 0.11M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.39M -0.90799M 0.21M -1.79578M 3.90M
Stock based compensation 2.38M 3.83M 2.56M 1.47M 1.42M
Other non cash items -1.68100M 0.50M -2.77832M 13.06M -0.29856M
Free cash flow -23.41000M -22.71996M -22.09775M -19.91703M -12.02770M

Fundamentals

  • Previous Close 1.57
  • Market Cap118.91M
  • Volume27263
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-33.36600M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.51

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ONC
Oncolytics Biotech Inc		 -0.01 0.64% 1.56 - - - 4.00 -2.3144
FRX
Fennec Pharmaceuticals Inc		 -0.19 2.00% 9.33 - 33.33 29.10 84.57 30.47 -23.3985
SVA
Sernova Corp		 -0.025 7.14% 0.33 - - - 7.95 -4.4095
EPRX
Eupraxia Pharmaceuticals Inc		 -0.01 0.25% 4.00 - - - 8.40 -3.9163
TH
Theratechnologies Inc.		 0.01 0.56% 1.81 - 55.25 1.64 19.46 2.23 -11.7353

Reports Covered

Stock Research & News

View All

Profile

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Inc

322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5

Key Executives

Name Title Year Born
Dr. Matthew C. Coffey M.B.A., Ph.D. Pres, CEO & Director NA
Mr. Kirk J. Look C.A., CA Chief Financial Officer NA
Mr. Andrew R. de Guttadauro Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc 1967
Dr. Thomas C. Heineman M.D., Ph.D. Chief Medical Officer NA
Ms. Allison Hagerman P.Eng., P.M.P. VP of Product Devel. NA
Jon Patton Director of Investor Relations & Communication NA
Dr. Grey Wilkinson Ph.D. Scientist of Translational Medicine NA
Mr. John Mark Lievonen F.C.A., FCA Consultant NA
Dr. Daniel Douglas Von Hoff F.A.C.P., FACP, M.D. Consultant 1948

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).